ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

ClinicalTrials.gov ID: NCT07228624

Public ClinicalTrials.gov record NCT07228624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Study identification

NCT ID
NCT07228624
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
50 participants

Conditions and interventions

Interventions

  • Allogeneic Hematopoietic Stem Cell Transplantation Procedure
  • Busulfan Drug
  • Computed Tomography Procedure
  • Cyclophosphamide Drug
  • Echocardiography Test Procedure
  • Ruxolitinib Drug

Procedure · Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 3, 2026
Primary completion
Aug 31, 2030
Completion
Aug 31, 2030
Last update posted
Feb 18, 2026

2026 – 2030

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fred Hutch/University of Washington Cancer Consortium Seattle Washington 98109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07228624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 18, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07228624 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →